ADC Manufacturing Report: Practices, Challenges, and Future Trends

Takeda is expanding its partnership with Nabla Bio to design new biologics using AI-powered models. Another example of the shift of use of AI from “experimental” to core R&D strategy. The focus now is speed and precision to get to focused candidates faster. Where do you see AI making the biggest impact first — molecule design, screening, or clinical planning? Teams that pair these new tools with biology are starting to separate themselves by turning AI into a real advantage instead of just a buzzword on a slide. #AIDrugDiscovery #BiotechInnovation #PharmaStrategy https://lnkd.in/eCeCfntd

Top ai use cases in pharma and biomedicine Read more : https://bit.ly/4oC1BLe Artificial Intelligence is transforming the pharmaceutical and biomedical industries by accelerating drug discovery, improving diagnostics, and enhancing patient outcomes. AI-powered algorithms analyze vast biological data to identify potential drug candidates faster than traditional methods. In biomedicine, AI supports precision medicine by predicting disease risks and personalizing treatment plans. Additionally, AI-driven imaging tools assist in early disease detection and clinical trial optimization. #pharma #biomedicine #diagnostic #clinical #artificialintelligence #mobileappdevelopment #iosappdevelopment #androidappdevelopment #MachineLearning #business #technology

💡AI is transforming drug discovery - fast. From small molecules to biologics, AI is accelerating design, improving precision, and unlocking new therapeutic possibilities. Rouken Bio explores how deep learning, generative models, and closed-loop systems are reshaping antibody development and targeting complex diseases. 🔬 The future? Autonomous, personalised biologics - validated by wet lab expertise. 📖 Read more: 👉 https://bit.ly/4ofr9O2 #AIinBiotech #DrugDiscovery #Biologics #PrecisionMedicine #RoukenBio #ImmunologyCRO

A perspective on AI driven therapeutic discovery from Aimee Cliens. The successes, and the remaining challenges. #AItherapeutics #antibodytherapeutics #drugdiscovery #biologics

RoukenBio, this is an excellent deep dive into the accelerating role of AI in drug discovery. We fully agree that the future lies in combining the predictive power of computational tools with robust experimental validation. At MAbSilico, we employ a fully integrated AI-driven pipeline followed by experimental validations in our wet-lab, that significantly de-risks and accelerates the antibody discovery curve. Our methodology is built on a few core pillars: 1. Design & Prediction: We use structure-based biophysics to generate, optimize or characterize antibodies. 2. Multi-Parametric De-risking: We profile hits for developability (aggregation risk, PTM liabilities...) and off-target binding before we commit to costly wet-lab experiments. This ensures that the candidates advancing for synthesis have the highest probability of success. 3. Strategy & IP: Our MAbFactory platform with the most extensive manually curated data set from thousands of patents to map the competitive and epitope landscape of any target allows discovery teams to potentially identify novel epitopes giving the program built-in Freedom-to-Operate (FTO) advantage. The key is that the computational solutions do not just suggest hits; they deliver pre-validated, high-quality candidates to the wet lab, making the screening process more efficient and focused. We are happy to discuss, feel free to reach out! #AIDiscovery #Techbio #Biotech #DrugDesign #InSilico #Biologics #AntibodyEngineering #DrugDiscovery

"Artificial intelligence in drug development" - Nature Medicine An interesting overview of the recent advancements with AI in drug development. This paper summarizes how AI can be involved from identification of disease targets, drug discovery, preclinical and clinical studies and post-market surveillance. Though AI has its challenges and limitations, the evolving advancements and refinement of AI has the potential to improve the efficiency and cost-effectiveness of drug development in the coming future. #AI #DrugDevelopment #Pharma #Biotech

The "ABC" model — #AI + #BioTech / #BioPharma + #CXO — is reshaping the competitive landscape of the #ADC field. A new tripartite collaboration between Insilico Medicine, 迈威（上海）生物科技股份有限公司, and ChemExpress integrates cutting-edge capabilities across the drug development chain: from AI-driven molecule design, to antibody engineering, to small molecule synthesis. Key advantages of this integrated approach: ▫️ Parallel Development – shortening R&D cycles ▫️ Platform-driven Innovation – enabling modular, Lego-like candidate assembly ▫️ Optimized Therapeutic Window – through co-designed linker and payload strategies This synergy marks a shift from siloed progress to end-to-end collaboration — accelerating the future of ADC therapeutics. Read the full analysis here 👉 https://lnkd.in/eK2n4YyH #DrugDiscovery #Biotech #PrecisionMedicine #Innovation

🚀 Revolutionizing Drug Discovery with AI! Insilico Medicine is radically transforming how new medicines are found, tackling the historically slow and expensive preclinical drug development process head-on. Their end-to-end Pharma.AI platform (featuring PandaOmics and Chemistry42) acts as an autonomous agent, analyzing vast datasets to discover novel targets and generatively design new molecules in record time. Key results that speak volumes: Reduced preclinical candidate nomination time to as little as 9 months (vs. 2.5-4 years industry average). Cost of a lead candidate program cut to just $2.6 million (vs. hundreds of millions traditionally). 10 programs advanced to IND stage since 2021, with their lead anti-fibrotic drug now in Phase II clinical trials – entirely AI-discovered and designed! This isn't just automation; it's a paradigm shift, proving the immense power of agentic AI to bring life-changing therapies to patients faster and more efficiently. Panaversity #AIDrugDiscovery #Biotechnology #PharmaAI #InsilicoMedicine #Innovation #Healthcare #ArtificialIntelligence #Panaversity

MOLCURE Joins Forces with Boehringer Ingelheim to Discover and Develop Innovative Antibody Drugs for Multiple Targets Using Its AI-driven Platform Technology https://lnkd.in/eAxnihvr #biotech #AI #antibody MOLCURE Inc. Boehringer Ingelheim

Merck KGaA and Siemens have expanded their partnership to transform drug discovery and development with integrated digital and AI solutions. Following Siemens’ acquisition of Dotmatics (now Dotmatix), this collaboration will create unified digital workflows connecting research, development, and manufacturing. This partnership advances a digital-first, data-driven future for life sciences, enabling scientists to deliver life-changing therapies faster. #DrugDiscovery #LifeSciences #Biotechnology